Article Sidebar

PDF
Date Published: 24/10/2021
Abstract Views: 731
Views PDF: 383
DOI: https://doi.org/10.51298/vmj.v506i2.1263
Issue
Vol. 506 No. 2 (2021)
Section
Các bài báo
How to Cite
Viết Nam, L. ., & Cẩm Phương, P. . (2021). EVALUATING THE RESULTS OF CHEMOTHERAPY WITH PEMETREXED REGIME IN STAGE IIIB-IV NON-SMALL CELL LUNG CANCER AT BACH MAI HOSPITAL. Vietnam Medical Journal, 506(2). https://doi.org/10.51298/vmj.v506i2.1263

EVALUATING THE RESULTS OF CHEMOTHERAPY WITH PEMETREXED REGIME IN STAGE IIIB-IV NON-SMALL CELL LUNG CANCER AT BACH MAI HOSPITAL

Lê Viết Nam1,, Phạm Cẩm Phương1
1 Nuclear Medicine and Oncology Center, Bach Mai Hospital

Main Article Content

Abstract

Objective: To evaluate the results of chemotherapy with pemetrexed in stage IIIB-IV non-small cell lung cancer at Bach Mai Hospital. Subjects and Methods: A retrospective and prospective descriptive study on 63 adenocarcinoma lung cancer patients with stage IIIB-IV who received chemotherapy with pemetrexed at Bach Mai Hospital since June 2018 to June 2021. Results: Mean age: 61.5 ±7.2; the oldest patient: 74; male/female ratio: 1.75/1; 76,3% of patients achieve clinical symptoms response; of which 16,9% respond completely; Ratio response: 38.1% partial response, 39.1% stable disease, 20.6% progressive disease and 1 patient complete response; Median progression-free survival was 8.2 months (CI 95%: 7.1-9.5); median overall survival was 16,0 months; (CI 95%: 14.2 17.8); Good performance status (ECOG) improves response rates, prolongs progression-free survival and overall survival. Conclusion: Treatment of stage IIIB-IV adenocarcinoma lung cancer with chemotherapy with pemetrexed improves response rate and survival time.

Article Details

Keywords

pemetrexed, non-small cell lung cancer

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
2. Joshi A., Noronha V., Patil V.M. et al. (2017). Efficacy of Second Line Pemetrexed - carboplatin in the treatment of metastasis nonsmall cell lung cancer . Chemother Res Pract.
3. Lung Cancer TNM 8th edition. www.nccn.org/ physician_gls/nscl.pdf
4. Trương Văn Sáng (2019). Đánh giá kết quả điều trị phác đồ pemetrexed – carboplatin trên bệnh nhân ung thư biểu mô tuyến của phổi giai đoạn IV. Luận văn thạc sĩ y học. Trường Đại Học Y Hà Nội.
5. Đinh Ngọc Việt (2014). Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn IV bằng phác đồ docetaxel và carboplatin, Luận văn thạc sỹ y học, Đại học Y Hà Nội
6. Ito M., Horita N., Nagashima A. et al. (2018). Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non small cell lung cancer: Meta analysis. Asia Pac J Clin Oncol
7. Scagliotti G.V. (2005). Pemetrexed plus carboplatin or oxaliplatin in advanced non small cell lung cancer. Semin Oncol, 32(2 Suppl 2), S5-8
8. Metro G., Chiari R., Mare M.et al. (2011). Carboplatin plus pemetrexed for platinum pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol, 68(6), 1405–1412.
9. Hàn Thị Thanh Bình (2018). Nghiên cứu điều trị ung thư phổi không tế bào nhỏ giai đoạn IIB,IV bằng hóa trị phác đồ cisplatin kết hợp với paclitaxel hoặc etoposide. Luận án tiến sĩ y học. Trường Đại học Y Hà Nội
10. Zinner R.G., Fossella F.V., et al. (2005). Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer, 104(11), 2449–2456.